Bleb Formation in Human Fibrosarcoma HT1080 Cancer Cell Line Is Positively Regulated by the Lipid Signaling Phospholipase D2 (PLD2)

Introduction

PLD2 positively regulates bleb formation

Blebs are spherical, blister-like plasma membrane protrusions which are formed by actomyosin-propelled cortex contractility thereby detaching the membrane from the underlying cortex which is under constant strain due to the sliding activity of myosin motors with actin filaments (Tinevez et al., 2009). These blister-like protrusions which appear and disappear within short interval of time are also caused by local breakage of the cortex itself (Charras and Paluch, 2008). Although observed for a very long time in different cell types (Kubota, 1981, Trinkaus, 1973), there are now ample evidences that cancer cells metastasize through pre-existing pores in the extracellular matrix (ECM) using plasma membrane blebbing as an alternative mode of migration (Ridley, 2011, Wolf et al., 2003).

The life cycle of a cellular bleb is divided into three phases: nucleation, expansion (bleb growth) and retraction. Bleb nucleation is triggered by extracellular stimuli such as experimental techniques involving two-photon laser ablation of the cortex thereby creating a weaken cortex-membrane interaction (Goudarzi et al., 2012) and this subsequently bulges the membrane from the cortex. The growth phase which lasts between 5 and 30 s, is caused by the generation of hydrostatic pressure in the cytoplasm by actomyosin contractility. The bleb becomes enlarged in volume as cytosolic fluid and lipid flow through the bleb neck into the bleb resulting in an increase in the surface area of the bleb (Charras and Paluch, 2008). Bleb expansion gradually subsides as the rate of actomyosin contractility-dependent fluid and lipid influx becomes inadequate to sustain a continuous growth (Charras et al., 2006). Thus, an expanding bleb attains a brief steady state (bleb stabilization) before retraction begins. Retraction is the longest phase and can last up to 2 min (Charras et al., 2008). It is accompanied first by recruitment of membrane-cortex linker proteins (ezrin, radixin and moesin) within the bleb membrane before reassembling of actin filaments at the bleb membrane. This is followed by recruitment of motor proteins, especially myosin II (Charras et al., 2006). The bleb is then retracted by the newly formed cortex towards the cell body (Norman et al., 2010).

The lipid signalling phospholipase D (PLD) exists in two isomeric forms as PLD1 and PLD2, and catalyses the hydrolysis of the phosphodiester bond of membrane phospholipid phosphatidylcholine (PC) to yield phosphatidic acid (PA) and free choline (Su et al., 2009a). Whereas the free choline diffuse away from the membrane, the versatile lipid second messenger PA remains in the membrane to mediate biological processes such as signal transduction (Zhao et al., 2007), cell proliferation (Oude Weernink et al., 2007), membrane vesicle trafficking (Shen et al., 2001), lipid metabolism (Wagner and Brezesinski, 2007), actin cytoskeletal reorganization (Du and Frohman, 2009), phagocytosis and exocytosis (Corrotte et al., 2006, Shen et al., 2001), cell survival (Foster, 2009), and cell migration (Scott et al., 2009, Su et al., 2009b). Thus, impairment of PLD activity has been correlated with pathological conditions such as cancer, neurodegeneration, diabetes and inflammation (Selvy et al., 2011).

In this study, we investigated the role of PLD in formation of membrane blebs in human fibrosarcoma HT1080 cell line, a cell line which has been previously reported to profusely bleb upon inhibition of proteolysis and matrix degradation (Wolf et al., 2003). This makes the HT1080 cell line an excellent model in studying membrane bleb formation in an in vitro setting, and this informed our choice of this cell line for this study. We demonstrate that in HT1080 cells cultured in 3D matrigel matrix, PLD2, but not PLD1 signals through PA to mediate bleb formation in a mechanism that requires the LPA-LPAR-ROCK (lysophosphatidic acid/lysophosphatidic acid receptor/Rho-associated kinase) signalling pathway. Thus, development of novel PLD2-specific inhibitors is a promising therapeutic strategy in fighting cancer.

Material and Methods

Cell Culture and Reagents

Human fibrosarcoma HT1080 cell line was obtained from HPA culture collections, Salisbury, UK. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) foetal bovine serum, 1% (2 mM) l-glutamine, 1% (100 Î¼g/ml) streptomycin, and 1% (100 units/ml) penicillin at 37 Â°C in humidified 5% (v/v) CO2 atmospheric air. Cells were maintained and passaged every 48 h. Smartpool human PLD1 and PLD2 siRNAs were purchased from Fisher Scientific, Loughborough, UK. Antibodies against PLD1 and PLD2 were obtained from Abcam Plc, Cambridge, UK. Batimastat (BB-94), FIPI (5-fluoro-2-Indolyly des-chlorohalopemide), Go6976, LY294002, PIC set VI (protease inhibitor cocktail VI), U73122, and Y27632 were purchased from Calbiochem, Nottingham, UK. VPC-32138 was a kind gift from Prof Ketan Patel (University of Reading, UK). All inhibitors except PIC which was reconstituted in dH2O, were dissolved in DMSO.

siRNA Transfection

The transfection of HT1080 cell lines was performed using DharmaFECT transfection reagent set 4 (T-2004-02) according to the manufacturer’s instruction. Briefly, cells were seeded on 6-well plate at a density of 2 Ã— 105 cells/well and incubated at 37 Â°C with 5% CO2 for 24 h before transfection. From a 20 Î¼M stock siRNA, 5 Î¼M siRNA solution was prepared in 1 Ã— siRNA buffer (20 mM KCl, 6 mM HEPES (pH 7.5), and 0.2 mM MgCl2), which itself was prepared from 5 Ã— siRNA buffer (300 mM KCl, 30 mM HEPES (pH 7.5), 1.0 mM MgCl2) and RNase-free water at a ratio of 1:4. Two tubes were set up. To the first and second tubes, an appropriate volume of the 5 Î¼M siRNA solution and DharmaFECT transfection reagent were respectively introduced. Media supplemented with only l-glutamine (antibiotic- and serum-free media) was introduced into each tube and both tubes were incubated for 5 min in the hood. After incubation, the content of the first tube was added to the second and the resulting mixture was resuspended and allowed to complex for 20 min before adding antibiotic-free media to the mixture. Culture media from cells in 6-well plate was replaced with 2 ml of the total transfection medium before incubating for 24 and 48 h. The final siRNA concentration used was 25 nM, and knockdown of proteins was confirmed by Western blotting.

Blebbing Assay

The blebbing assay was a modification of a 3D cell migration assay previously designed (Wolf et al., 2003). In that study, Wolf and colleagues reported that the human HT1080 cell line not only exhibited plasticity, that is, an interconversion from elongated mesenchymal form into a rounded amoeboid mode of migration, a process referred to as mesenchymal amoeboid transition (MAT), but that the cells do profusely form membrane blebs upon inhibition of proteolytic activities of matrix metalloproteinases (MMPs) and other proteases (Wolf et al., 2003). Thus, the cell line is a good model for studying membrane bleb formation. Briefly, growth factor-reduced matrigel (BD Biosciences, UK) was thawed overnight at 4 Â°C and kept on ice. Tips, pipettes, plates, glass coverslips, μ-dishes and tubes were chilled at − 20 Â°C for 1 h. Confluent cells were rinsed with phosphate buffered saline (PBS), trypsinized and then resuspended in cold serum-free media. Cell suspension was carefully added on ice to matrigel in an equivalent ratio and mixed properly. 200 Î¼l of cell-matrigel suspension was plated on glass coverslips in 6-well plates, and on 35 mm glass-bottomed dishes and then incubated at 37 Â°C for 30 min for matrigel to set. Complete cell culture media was added and cells were induced to bleb by blocking proteolytic activities of (MMPs) and surface proteases with batimastat, BB-94 (1 Î¼M) and protease inhibitor cocktail, PIC (1:100) respectively in the presence of caspase inhibitor set VI (10 Î¼M) which inhibits apoptotic bleb formation. Plates were then incubated at 37 Â°C for 18 h.

Fixation of Cells and Phase Contrast Microscopy

After bleb induction with BB-94 and PIC, media was aspirated and cells were rinsed twice with pre-chilled PBS and then fixed for 30 min with 2.5% (v/v) glutaraldehyde. Fixative was removed and cells permeabilized with 0.2% (v/v) triton X-100 for 30 min. Images were acquired using a 40 Ã— phase-contrast objective lens of a Zeiss A1 inverted microscope.

Determination of Bleb Size

The sizes (circumference) of blebs in each individual cell were measured by manually drawing a thin circular line round the entire circumference with the ‘polygon tool’ of ImageJ. This was followed by ‘analyze > measure’, and from the dropdown result list, the perimeter values in pixel were recorded. Values in pixel were normalized by multiplying with a pre-calibrated factor of 0.11 Î¼m (a factor which corresponds to 1 pixel, and which was obtained when 40 Ã— objective lens was calibrated with a graticule).

Quantification of Percentage Blebbing Cells

For quantification of the percentage of blebbing cells, plates and μ-dishes were properly fitted on the stages of a phase contrast Zeiss A1 inverted microscope, and the total number of cells (blebbing and non blebbing cells) were visualized using 40 Ã— objective lens, and manually counted. The percentage of blebbing cells was obtained by dividing the number of blebbing cells by the sum of blebbing and non blebbing cells, and then multiplying the result by 100 as shown below:%Blebbingcells=NoblebbingcellsTotalNocell×1001.

Western Blotting

HT1080 cells were seeded on 6-well plate overnight and treated with PLD1 and PLD2 siRNAs. Cells were harvested and lysed in radioimmunoprecipitation assay (RIPA) buffer in the presence of protease inhibitor cocktail (1:100). Proteins were electrophoresed on 10% polyacrylamide gels before transferring to PVDF membranes and blocked with 5% non-fat milk in 0.1% TBS-tween. Membranes were incubated overnight at 4 Â°C with human anti-PLD1 and PLD2 antibodies (Abcam, ab10583 and ab123663) (1:1000). Anti-tubulin antibody (Sigma; T9026) was used as a loading control. Secondary antibodies used were anti-rabbit and anti-mouse IgG-HRP (1:2000). Membranes were treated with enhance chemiluminescence (ECL) reagents A and B, and then developed with ImageQuant LAS 4000 machine (GE Healthcare Life Sciences).

Statistical Analysis

Statistical significance was performed by one-way analysis of variance after Tukey’s post-hoc multiple comparison for three or more variables, while unpaired, two-tailed Student’s t test was performed for two variables. GraphPad prism 5 software (GraphPad software, San Diego, CA) was used to perform all comparisons. All data were generated from at least three independent experiments in triplicate (n = 3), and P values < 0.05 were considered statistically significant.

Results

Pharmacological Inhibition of Phospholipase D (PLD) Activity

To investigate the role of lipid signalling mediated by PLD1 and PLD2 in blebbing of HT1080 cells in the extracellular matrix (ECM), cells were first induced to bleb by blocking the activities of MMPs and proteases with BB-94 (1 Î¼M) and protease inhibitor cocktail PIC (1:100) respectively in the presence of caspase inhibitor (10 Î¼M). The activity of PLD1 and PLD2 was then inhibited with 5-fluoro-2-indolyl des-chlorohalopemide (FIPI), a potent universal inhibitor of the two PLD isoforms both in vitro and in vivo (Su et al., 2009b). As shown in Fig. 1A (top panel), inhibition of matrix proteolysis with PIC and BB-94 effectively converted cells from elongated mesenchymal mode into a rounded amoeboid mode filled with membrane blebs (middle panel). However, pre-treatment of cells with 750 nM FIPI for 30 min sufficiently suppressed bleb formation in HT1080 cells (bottom panel), suggesting that either PLD1 or PLD2 or both mediate bleb formation in this cell line. Upon quantification it was revealed that FIPI treatment significantly reduced the percentage of blebbing cells from 83% to 12% (Fig. 1B). Treatment of cells with the PLD inhibitor also drastically reduced the number of blebs per cell (Fig. 1C) as well as the sizes of blebs (Fig. 1D).

Fig. 1.

siRNA-mediated Impairment of PLD2, but not PLD1 Inhibited Bleb Formation

To investigate whether inhibition of blebbing by FIPI was due to inhibition of PLD1 or PLD2, we used specific smartpool siRNAs that target PLD1 and PLD2 at four different sequences. Knockdown of PLD1 and PLD2 was observed 24 h post-siRNA transfection as confirmed by Western blotting (Fig. 2A and B). PLD1 and PLD2 knocked down cells as well as scrambled siRNA-treated cells were then cultured in 3D matrigel matrix and challenged with BB-94 (1 Î¼M) and PIC (1:100) in the presence of caspase inhibitor (10 Î¼M). As shown in Fig. 2E, knockdown of PLD1 had no effect on bleb formation, whereas in a manner similar to FIPI treatment, PLD2 RNA interference inhibited formation of blebs in HT1080 cells (Fig. 2F). Analysis of bleb numbers and size revealed that PLD2 siRNA significantly reduced both bleb number and size, while PLD1 siRNA showed no difference in both bleb numbers and size when compared to original blebbing cells (Fig. 2G and H).

Fig. 2.

Isoform Specificity of PLD1 and PLD2 siRNAs

As siRNAs could have off-target effects thereby negatively impacting on the other isoform, we tested the specificity of each siRNA by first probing PLD1 knocked down cell lysates with anti-PLD2 antibody, while PLD2 siRNA cell lysates were immunoblotted with anti-PLD1 antibody. As shown in Fig. 3A and B, PLD1 siRNA had no effect on PLD2. Similarly, PLD2 siRNA did not negatively impact on PLD1 activity (Fig. 3C and D), suggesting that the siRNAs used were specific to their target. This further confirms that PLD2, but not PLD1 positively regulates bleb formation in HT1080 cells.

Fig. 3.

PLD2 Signals through Phosphatidic Acid (PA) to Promote Bleb Formation

As most biological processes by the PLD enzymes are mediated by the lipid second messenger, phosphatidic acid (PA), it became imperative to investigate whether PLD2-mediated cell blebbing was via PA production. The involvement of PLD in most biological processes is tested for by using primary alcohols which are capable of undergoing transphosphatidylation reaction to block PA formation (Zouwail et al., 2005). Indeed, addition of 1% butan-1-ol to blebbing HT1080 cells for 5 min almost completely abolished bleb formation (Fig. 4A, lower middle panel), whereas addition of 1% tertiary butanol had no significant effects (Fig. 4A, bottom panel). Treatment with butan-1-ol drastically reduced percentage of blebbing cells to 5%, and number of blebs per cell to 1 (Fig. 4B and C).

Fig. 4.

PA Signals through Lysophosphatidic Acid (LPA) to Activate LPAR-Rho-ROCK Pathway

To further unravel the mechanism by which PA signals to mediate bleb formation, it was anticipated that PA could possibly promote bleb formation through its product lysophosphatidic acid (LPA) which usually binds its receptors (LPAR) at the plasma membrane. LPAR has been previously reported to function upstream of Rho-ROCK pathway to regulate blebbing in osteoclasts (Panupinthu et al., 2007), and in general, blebbing of cells is reported to be due to contraction of cortical actin mediated by ROCK signalling (Charras et al., 2008, Paluch and Raz, 2013). Indeed, inhibition of LPAR and ROCK with 1 Î¼M VPC-32183 and 5 Î¼M Y27632 respectively, inhibited bleb formation (Fig. 5B and C). A detailed analysis of number of blebs per cell revealed that LPAR and ROCK inhibition significantly decreased bleb numbers to 3 and 1 respectively, suggesting involvement of the PA-LPAR-Rho-ROCK signalling axis in blebbing of HT1080 cells.

Fig. 5.

Effect of Inhibition of Key Signalling Pathways on Bleb Formation

We further ascertained the contribution of key lipid signalling pathways in blebbing of HT1080 cells by using different pharmacological agents known to inhibit them. The involvement of phospholipase C (PLC) was tested using U73122, a drug reported to inhibit PLC activities in different cell lines (Ward et al., 2003). Use of 20 Î¼M of U73122 significantly reduced the size of blebs without any significant change in bleb numbers (Fig. 6B). The involvement of PLC led to the analysis of protein kinase C (PKC) which is stimulated by PLC-generated diacylglycerol (DAG). Thus, use of 5 Î¼M of the PKC inhibitor, Go6976 also resulted in significantly diminished bleb size (Fig. 6C and E) without effect on the number of blebs (Fig. 6F). The phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002 was used to test for the requirement of this pathway in blebbing of HT1080 cells. Again, use of 5 Î¼M of the PI3K inhibitor suppressed bleb formation (Fig. 6D) with no significant difference in bleb numbers (Fig. 6F) when compared to original blebbing cells.

Fig. 6.

Discussion

In different cell lines, lipid signalling phospholipase D (PLD) enzymes are known not only to preserve the architectural integrity of cellular or intracellular membranes, but mediate a plethora of biological processes through one of three mechanisms: through their lipid-hydrolyzing lipase activity mediated through phosphatidic acid (PA); through protein–protein interaction, or through their guanine nucleotide exchange factor (GEF) activity in case of PLD2 (Gomez-Cambronero, 2014). For instance, actin reorganization, membrane trafficking, cell adhesion, tumour growth and metastasis have been attributed to the activities of the mammalian PLD1 (Chen et al., 2012, Selvy et al., 2011, Zouwail et al., 2005), whereas PLD2 has been shown to mediate cell spreading, endocytosis, cell growth, cell migration by acting as GEF to RhoA and Rac1, invasion and metastasis in lymphoma cells (Du et al., 2004, Henkels et al., 2013, Jeon et al., 2011, Mahankali et al., 2011b, Zheng et al., 2006). Whereas PLD1 is known to have low basal activity which increases upon external stimulation, and localizes to perinuclear structures, Golgi apparatus and endoplasmic reticulum, PLD2 has a higher basal activity and exclusively localizes to plasma membranes (Chen and Exton, 2004).

In the present study, the role of the PLDs in blebbing of human fibrosarcoma HT1080 cell line in extracellular matrix (ECM) was investigated. This cell line was previously reported to exhibit plasticity which makes them interconvert from elongated mesenchymal mode of migration into a rounded amoeboid mode associated with profuse plasma membrane blebs with which they metastasize by squeezing through pre-existing pores in three dimensional (3D) structures upon inhibition of matrix degradation (Wolf et al., 2003). This makes this cell line the preferred choice for this study. Indeed, inhibition of matrix proteolysis with a combination of batimastat (BB-94), a broad spectrum matrix metalloproteinases (MMP) inhibitor and a cocktail of protease inhibitor (PIC) sufficiently induced bleb formation (Figs. 1A, 4A, 5A and 6A). An investigation of the involvement of PLD in blebbing of HT080 cells by first blocking the activities of both isoforms of mammalian phospholipase D, PLD1 and PLD2 using a small molecule inhibitor, 5-fluoro-2-indolyl des-chlorohalopemide (FIPI) which was previously shown to inhibit the activity of PLD1 and PLD2 both in vitro and in vivo (Zouwail et al., 2005), sufficiently suppressed bleb formation, drastically reducing bleb numbers and size, and plummeting the percentage of blebbing cells to 12% as against original bleb-induced cells which had 83% (Fig. 1B). This suggests that either PLD1 or PLD2, or both isoforms promote bleb formation in HT1080 cells. The mechanism by which FIPI inhibits blebbing of cells via inhibition of PLD1 and PLD2 is not known. However, it was previously reported that the drug acts directly to inhibit the phosphodiesterase activity of both PLD1 and PLD2 (Su et al., 2009b).

Since FIPI is a potent inhibitor of both PLD isoforms, we next performed knockdown experiments using RNA interference technique. The smartpooled siRNAs employed in this study target the proteins at four different sequences thereby ensuring more effective gene silencing with minimal or no off-target effects. In a manner similar to FIPI treatment, siRNA-mediated knockdown of PLD2 potently inhibited bleb formation, whereas PLD1 knockdown had no significant effect on bleb formation (Fig. 2A–H). To further confirm that the two PLD siRNAs did not have off-target effect by interfering with each other, we determined their specificity by immunoblotting PLD1 knocked down cell lysates with anti-PLD2 antibody, while the PLD2 knocked down samples were Western-blotted with anti-PLD1 antibody. Indeed, the siRNAs were specific to their targets as knockdown of PLD1 had no negative impact on PLD2 activity (Fig. 3A and B). Similarly, PLD2 knockdown did not affect PLD1 activity (Fig. 3C and D), further demonstrating that it was actually PLD2, and not PLD1 that is involved in bleb formation in HT1080 cells.

Interaction of PLD2 with different adaptor proteins is known to regulate plasma membrane protrusions. For instance, PLD2 binding to growth factor receptor-bound protein 2 (Grb2) has been implicated in formation of plasma membrane ruffles, an event that preceded lamellipodia formation and enhanced cell migration and chemotaxis (Gomez-Cambronero, 2011, Mahankali et al., 2011a). PLD2 promotes phagocytosis through an interaction in which Grb2 acts as a docking protein between PLD2 and Wiscott-Aldrich syndrome protein (WASP) (Kantonen et al., 2011). Similarly, in a microtubule-dependent manner, formation of membrane protrusions in v-Src-transformed fibroblasts has been attributed to PLD2 (Shen et al., 2002). Since bleb formation, unlike formation of lamellipodia, filopodia, invadopodia and other membrane protrusions is independent of actin polymerization, it is possible that PLD2 might be signalling to stimulate actomyosin contractility.

Attempt to elucidate the mechanism by which PLD2 promotes bleb formation in HT1080 cells implicated phosphatidic acid (PA) – the catalytic product of the lipase reaction of PLD2 and which acts as an intracellular second messenger, as the signalling molecule through which PLD2 could be mediating cell blebbing. Usually, in most biological systems, the intracellular levels of PA is used as a read-out for PLD activity, and it is also known that mammalian PLD2 can exert its physiological functions by either signalling through protein–protein interactions or through a unique GEF activity (Gomez-Cambronero, 2014). On the other hand, the involvement of PLD in most biological processes is detected by use of primary alcohols which are preferentially used instead of water by PLD to generate stable phosphatidylalcohol which unlike PA, is unable to yield diacylglycerol (DAG) and lysophosphatidic acid (LPA), and it is also unable to recruit and activate downstream target proteins (Oude Weernink et al., 2007). Thus, in the presence of primary alcohols such as butan-1-ol, PA production is not only blocked, but other downstream signalling events are halted. Indeed, pre-treatment of HT1080 cells with 1% (v/v) butan-1-ol resulted in a near total loss of membrane blebs (Fig. 4A, lower middle panel) with only 5% cells forming membrane blebs (Fig. 4B), whereas pre-treatment with same concentration of tertiary butanol had no effect on bleb formation (Fig. 4A bottom panel, and B). Butan-1-ol-mediated depletion of PA also significantly suppressed the number of blebs appearing in the cell line (Fig. 4C). This suggests that PLD2-mediated cell blebbing is via PA, which interestingly, has been previously linked to leucocyte cells migration through regulation of lamellipodia structures and membrane ruffles (Gomez-Cambronero, 2014).

Furthermore, the mechanism as well as the downstream signalling pathway by which PLD2-derived PA promotes cell blebbing was investigated. One possible mechanism could be via the hydrolytic activity of phospholipase A1 or A2 (PLA1/PLA2) on PA to produce the ubiquitously expressed lysophosphatidic acid (LPA) which binds its receptors (LPAR) at the plasma membrane to trigger downstream effectors (Stoddard and Chun, 2015). LPAR has been reported to be involved in matrix degradation by upregulating MMP activities, cell proliferation, tumour progression and metastasis of different cancers via stimulation of Rho activity to activate ROCK (Gotoh et al., 2012, Jeong et al., 2012, Jeong et al., 2013). Importantly, LPAR has been shown to induce membrane blebbing in osteoclast via the ROCK signalling pathway (Panupinthu et al., 2007). Indeed, inhibition of LPAR with VPC-32183, a potent LPAR inhibitor abrogated bleb formation in HT1080 cell line (Fig. 5B). It is worth mentioning that LPA can also be produced by the action of lysophospholipase D (autotaxin) on lysophosphatidylcholine (LPC) which itself is produced from phosphatidylcholine (PC) by PLA2. Whether this pathway is involved in blebbing of HT1080 cells was not confirmed, however, it was previously reported that the pathway was unlikely to be involved in ATP-induced blebbing of osteoclast as autotaxin is not inhibited by butan-1-ol (Panupinthu et al., 2007).

The contribution of lipid signalling to blebbing of HT1080 cells was further assessed by probing key lipid signalling molecules. Cellular phosphatidylinositol 4,5-bisphosphate (PIP2) pool is regulated by phospholipase C (PLC) to yield diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3) which activates protein kinase C (PKC) and intracellular Ca2 + release respectively. Similarly, PIP2 can also be regulated by the activity of phosphatidylinositide 3-kinase (PI3K) to generate PIP3. PIP2 levels usually bolster the interaction between the plasma membrane and the cytoskeleton, and it also strengthens the activity of the ERM (ezrin, radixin, moesin) proteins (Zhao et al., 2014). Consistent with this, depletion of PIP2 levels enhanced fixation-induced blebbing of human umbilical vein endothelial cells (HUVEC) (Zhao et al., 2014). In the present study, accumulation of cellular PIP2 levels by using U73122 and LY294002 to inhibit PLC and PI3K activities respectively, significantly suppressed he sizes of blebs formed in HT1080 cells, but without any significant effect on bleb numbers. Inhibition of PKC with its known inhibitor Go6976 had similar effect as use of U73122 and LY294002, suggesting that cell blebbing involves a complex cascade of events regulated by most of the numerous plasma membrane lipids and signalling pathways that maintain the architectural integrity of the cell.

Conclusions

In conclusion, this study has demonstrated for the first time the novel role of PLD2 in the regulation of plasma membrane blebs in human fibrosarcoma HT1080 cell lines. Specifically, we demonstrated that PLD2, but not PLD1 is involved in bleb formation in HT1080 cell line in a mechanism that requires the PA-LPAR-Rho-ROCK signalling pathway. This could be exploited in the development of specific therapeutic agents to curb metastasis of different cancers of connective tissues. Similarly, a combination therapeutic approach targeting PLD2 and other lipid signalling molecules in the cell membrane would yield more effective results in the fight against fibrosarcoma and perhaps other human cancers.

Conflicting Interests

The authors declared that there are no conflicting interests.

Funding Information

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgements

We would like to thank the Department of Biomedical Sciences in the School of Biological Sciences, Faculty of Life Sciences at the University of Reading, England, UK for providing conducive environment for this study.

References

Posted in:science

Leave a Reply

Your email address will not be published. Required fields are marked *

error: Content is protected !!

Price Based Country test mode enabled for testing Cameroon. You should do tests on private browsing mode. Browse in private with Firefox, Chrome and Safari